Lack of demand forces uniQure to withdraw Glybera gene therapy in Europe – Pharmaceutical Business Review
|
Lack of demand forces uniQure to withdraw Glybera gene therapy in Europe
Pharmaceutical Business Review The marketing authorization of the gene therapy was approved in 2012 for the treatment of patients with familial lipoprotein lipase deficiency (LPLD). According to the Dutch gene therapy company, the usage of Glybera has been quite narrow and it would … |
